Holen Sie sich die Stockscreener-App
16.75
0.39%
0.065
Handel nachbörslich:
16.82
0.065
+0.39%
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Raises Target Price to $20 - Moomoo
Summit Therapeutics Stock Climbs Wednesday: What's Happening? - Benzinga
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - 247wallst.com
Leerink Partners Sticks to Its Hold Rating for Summit Therapeutics (SMMT) - theglobeandmail.com
Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT) - theglobeandmail.com
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - reuters.com
AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug - MedCity News
AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says - marketscreener.com
SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet - StocksToTrade
Summit Therapeutics Rises as AstraZeneca Backs Ivonescimab With $2 Billion Investment - Quiver Quantitative
Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab - Seeking Alpha
How Summit Therapeutics Stock Could Surge 162% After AstraZeneca Investment - Barron's
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics - Pharmaceutical Executive
Summit Therapeutics Stock Jumps On $2B AstraZeneca Deal - timothysykes.com
AstraZeneca Invests in Summit Therapeutics after Year of Speculation - Benzinga
AstraZeneca Invests $2B in Summit for Cancer Drug Dev - Rediff MoneyWiz
Summit Therapeutics Stock Jumps On $2B AstraZeneca Deal And Trial Wins - StocksToTrade
Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Australia
Summit Therapeutics Soars On $2B AstraZeneca Bet And Trial Wins - StocksToTrade
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab - Benzinga
Form 8K Summit Therapeutics PLC ADR For: 29 September By Investing.com - Investing.com Nigeria
AstraZeneca to invest $2bn in Summit for ADC combination therapies - Yahoo Finance
Goldman Sachs reiterates Summit Therapeutics stock rating on AstraZeneca deal - Investing.com Canada
Summit Therapeutics Shares Rise 22% After $2 Billion AstraZeneca Investment - Yahoo Finance
Summit soars after $2 billion investment from AstraZeneca for cancer therapies - reuters.com
Summit Therapeutics Raises $2.0 Billion in Convertible Preferred Private Placement With AstraZeneca - TradingView
AMD, Nvidia, Navitas, Summit Therapeutics, Fair Isaac, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
AstraZeneca invests $2bn in Summit Therapeutics - marketscreener.com
AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer - Cambridge Network
AstraZeneca invests $2bn in Summit Therapeutics to develop cancer drug - Business Weekly
AstraZeneca invests $2B in Summit Therapeutics for ADC trials By Investing.com - Investing.com Australia
Summit Therapeutics Inc. stock jumps on AstraZeneca’s $2B deal, but chart stays weak - The Cryptonomist
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Proactive financial news
Summit Therapeutics agrees to US$2B AstraZeneca equity investment - Mugglehead Investment Magazine
AstraZeneca invests $2 billion in Summit Therapeutics By Investing.com - Investing.com South Africa
Summit Therapeutics (SMMT) Secures $2B AstraZeneca Investment, S - GuruFocus
Update: Summit Therapeutics Shares Jump as AstraZeneca's Plan to Invest $2 Billion - Yahoo Finance
AstraZeneca to invest USD2 billion in Summit Therapeutics - marketscreener.com
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs - WSJ
Summit shares surge after-hours on $2 billion AstraZeneca equity deal - Yahoo Finance
Summit Therapeutics rises after AstraZeneca commits $2B investment - TradingView
Summit Therapeutics Jumps on $2 Billion AstraZeneca Deal - Bloomberg.com
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics - Business Wire
Summit Therapeutics Inc. announced that it expects to receive $2 billion in funding from AstraZeneca PLC - marketscreener.com
Bernstein Reaffirms Their Hold Rating on Summit Therapeutics (SMMT) - The Globe and Mail
SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results — Investors Await Q2 Earnings - stocktwits.com
Why Is SMMT Stock Tumbling Today? - stocktwits.com
Summit Therapeutics Inc. (SMMT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Summit Therapeutics plc (SMMT) stock price, news, quote and history - Yahoo Finance UK
Summit Therapeutics Inc. (SMMT) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Nigeria
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESM - BioSpace
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):